Intrasense Obtains CE Certification for DUOnco™ Pancreas, a Breakthrough in Oncology

Intrasense announced that its DUOnco™ Pancreas product has received CE certification, strengthening its position in oncology innovation. This medical imaging software uses artificial intelligence to help detect pancreatic cancer early, which is often difficult to diagnose. By enabling the identification of lesions at an early stage, it could triple the five-year survival rate of patients. This solution marks a strategic milestone for Intrasense, paving the way for its rollout in Europe in accordance with MDR regulations.

Designed to automatically analyze CT images, DUOnco™ Pancreas highlights subtle pancreatic lesions by prioritizing detected abnormalities. It is part of the DUOnco™ series, developed with Guerbet, aimed at enriching multi-organ detection in oncology. This certification thus attests to Intrasense's commitment to providing clinical tools valued by radiologists, supporting public health.